Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer.

Abstract excerpt

Gain-of-function mutations in the androgen receptor (AR) are found in prostate cancer and are implicated in the failure of hormone therapy. Most studies have emphasized the ligand-binding domain (LBD) where mutations can create promiscuous receptors, but mutations in the NH(2)-terminal transactivation domain have also been found. To assess AR alteration as a mechanism of treatment resistance, a mouse model...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Androgen Antagonists
• Share to Antineoplastic Agents